, /PRNewswire/ -- The global size is estimated to grow by million from 2024 to 2028, according to Technavio. The market is estimated to grow at a CAGR of 3.69% during the forecast period.
To understand more about this market - is set to contribute 39% to the growth of the global premenstrual syndrome (PMS) market during the forecast period. This growth is driven by factors such as an ageing population, the rising prevalence of chronic diseases, and high healthcare spending. The US, with its strong healthcare system and large patient population, leads this market.
Increased awareness about PMS is prompting more individuals to seek treatment. The region offers a variety of treatment options, including prescription medications, over-the-counter pain relievers, hormonal therapies, herbal supplements, and lifestyle management, ensuring continued demand and market growth. For more insights on significant contribution along with the market share of rest of the regions and countries - The analgesics segment, encompassing NSAIDs like ibuprofen and acetaminophen, is poised for significant market share growth.
Valued at in 2018, analgesics effectively relieve pain and inflammation, particularly aiding in alleviating menstrual cramps and related discomforts. With rising awareness about their efficacy for PMS symptoms like headaches and back pain, the analgesics market is set to drive substantial growth, paralleling the expansion of the global PMS market in the forecast period. Get a glan.
